Years of translational research have successfully improved treatment outcomes for common dermatological conditions such as ...

Vyne Therapeutics has dosed the first participant in a randomised Phase Ib clinical trial of VYN202, an oral treatment for moderate-to-severe plaque psoriasis. The double-blind, placebo-controlled ...

A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival ...

Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023 Full year 2024 total ...

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...

In biologics production, CM is an emerging technology aimed at improving yields, reducing costs, and streamlining production processes. However, despite its recent media attention, misconceptions ...

UK: A recent study, published in the British Journal of Dermatology highlighted the importance of age-specific strategies in biologic treatment for psoriasis. The study revealed that younger patients ...

Biologics are more targeted than other psoriasis treatments. They’re also more expensive, and you take them less frequently. Doctors usually prescribe them for moderate to severe psoriasis.

Patients aged 55 years and older are more likely to discontinue biologic treatment for psoriasis due to adverse events, whereas patients aged 16 to 24 years are more likely to discontinue treatment of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Psoriasis is a complex, chronic relapsing and inflammatory skin disorder with a prevalence of approximately 2% in the general population worldwide. Psoriasis can be triggered by infections, physical ...